STIM Stock Overview
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Neuronetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.83 |
| 52 Week High | US$5.07 |
| 52 Week Low | US$1.03 |
| Beta | 2.44 |
| 1 Month Change | -10.30% |
| 3 Month Change | 15.36% |
| 1 Year Change | 77.31% |
| 3 Year Change | -66.14% |
| 5 Year Change | -75.24% |
| Change since IPO | -86.21% |
Recent News & Updates
Recent updates
Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely
Mar 17
Neuronetics: Modest Improvements Are Not Enough
Jan 30Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward
Dec 19Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story
Jun 21Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?
May 10Neuronetics: Growth To Capture, But Fairly Priced
Sep 06Is Neuronetics (NASDAQ:STIM) Using Debt Sensibly?
Sep 06Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression
Aug 29Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance
Aug 02Neuronetics stock soars 30% as FDA clears NeuroStar system for anxious depression
Jul 19Is Neuronetics (NASDAQ:STIM) A Risky Investment?
Jun 08Is Neuronetics (NASDAQ:STIM) Weighed On By Its Debt Load?
Jan 19Is Neuronetics (NASDAQ:STIM) Using Debt In A Risky Way?
Oct 14Is Neuronetics (NASDAQ:STIM) A Risky Investment?
Jul 05Shareholder Returns
| STIM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -11.3% | -4.1% | -3.7% |
| 1Y | 77.3% | -2.2% | 20.5% |
Return vs Industry: STIM exceeded the US Medical Equipment industry which returned -2.2% over the past year.
Return vs Market: STIM exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| STIM volatility | |
|---|---|
| STIM Average Weekly Movement | 12.7% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: STIM's share price has been volatile over the past 3 months.
Volatility Over Time: STIM's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 203 | Keith Sullivan | neurostar.com |
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Neuronetics, Inc. Fundamentals Summary
| STIM fundamental statistics | |
|---|---|
| Market cap | US$114.80m |
| Earnings (TTM) | -US$30.19m |
| Revenue (TTM) | US$71.35m |
1.6x
P/S Ratio-3.8x
P/E RatioIs STIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STIM income statement (TTM) | |
|---|---|
| Revenue | US$71.35m |
| Cost of Revenue | US$17.74m |
| Gross Profit | US$53.61m |
| Other Expenses | US$83.79m |
| Earnings | -US$30.19m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 75.13% |
| Net Profit Margin | -42.31% |
| Debt/Equity Ratio | 173.4% |
How did STIM perform over the long term?
See historical performance and comparison